The Innovative Medicines Initiative (IMI) supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

IMI is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

IMI is the world’s biggest public-private partnership in the life sciences. Through the IMI 2 programme, it has a €3.3 billion budget for the period 2014-2024.

The following topics are under consideration for inclusion in future IMI Calls for proposals (11th Call):

  • Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s disease (RADAR-AD)
  • Fairification of IMI and EFPIA data
  • Development of sensitive and validated clinical endpoints in primary Sjögren’s syndrome (PSS)
  • European screening centre: unique library for attractive biology
  • Exploitation of IMI project results  (updated version of February 2017)

Visit the website.

Leave a Reply